AZRX AzurRx BioPharma Inc.

1.19
-0.03  -3%
Previous Close 1.22
Open 1.22
Price To Book 9.16
Market Cap 25,082,526
Shares 21,060,055
Volume 66,200
Short Ratio
Av. Daily Volume 133,448

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due late-summer 2019.
MS1819-SD (OPTION)
Cystic fibrosis
Phase 2 trial initiation announced July 8, 2019 with data due early 2020.
MS1819-SD
Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency

Latest News

  1. AZRX: Launch of Study for Cystic Fibrosis Patients With Severe EPI
  2. AzurRx BioPharma Announces R&D Update Call on Monday, July 8th at 4:30 PM ET
  3. AzurRx BioPharma Announces Initiation of Phase 2 Clinical Study for MS1819-SD in combination with standard PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency
  4. AzurRx BioPharma Announces Notice of Allowance of U.S. and Japan Patents Covering a MTAN Inhibitor for Treating H. Pylori Infections, the Primary Cause of Stomach Ulcers
  5. How Many AzurRx BioPharma, Inc. (NASDAQ:AZRX) Shares Did Insiders Buy, In The Last Year?
  6. AZRX: Secondary Endpoint Data Released for MS1819-SD in Chronic Pancreatitis Patients
  7. AzurRx BioPharma Reaches Enrollment Target for Phase II OPTION Clinical Trial
  8. AzurRx BioPharma Presents Positive Secondary Endpoint Data in its Phase II MS1819-SD Chronic Pancreatitis Study at the 2019 Digestive Disease Week Conference
  9. AzurRx BioPharma Exceeds 50% Enrollment Target for Phase II OPTION Clinical Trial
  10. AZRX: CF Study Up and Enrolling; Target to $8
  11. Expanded MS1819-SD Global Commercialization Rights Now Owned by AzurRx BioPharma along with Full Development Rights
  12. AzurRx BioPharma Announces Presentation on Its Positive Phase II Data in MS1819-SD in Chronic Pancreatitis at the 2019 Digestive Disease Week Conference
  13. AzurRx BioPharma to Present at the 2019 Annual Roth Capital Conference (March 19) and the Oppenheimer 29th Annual Healthcare Conference (March 20)
  14. AzurRx BioPharma Announces Poster Presentation at the Americas Hepato-Pancreato-Biliary Association 2019 Annual Meeting
  15. AzurRx BioPharma Announces First Patients Dosed in Phase II OPTION Clinical Trial
  16. What Kind Of Shareholder Owns Most AzurRx BioPharma, Inc. (NASDAQ:AZRX) Stock?
  17. AzurRx BioPharma Announces Initiation of Phase II OPTION Clinical Trial of MS1819-SD in Cystic Fibrosis Patients
  18. AzurRx BioPharma to Acquire Payment Rights to Lead Drug Candidate MS1819-SD from Protea Biosciences Group
  19. AZRX: 3Q:18 Financial and Operational Summary
  20. AzurRx BioPharma to Present at Upcoming Investor Conferences